Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All News Releases
        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Hamburger menu
    • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
    • Create a Free Account
      • ALL CONTACT INFO
      • Contact Us


        11AM ET Sunday – 8PM ET Friday

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Why PRWeb
    • Contact
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Sign up
      • Log in
      • Resources
      • RSS
      • GDPR
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Matter Bio Initiates First-in-Human Clinical Trial of Novel Immunotherapy for Advanced Pancreatic Cancer


      News provided by

      Matter Bio

      Nov 18, 2026, 17:50 ET

      Share this article

      Share this article



      Phase 1 study evaluating Lm-LLO-TT, a novel Listeria-based immunotherapy designed to harness existing immune memory against cancer, is now recruiting patients.

      SAN FRANCISCO, Nov. 18, 2026 /PRNewswire-PRWeb/ -- Matter Bio, a biotechnology company developing innovative therapies targeting the underlying biology of disease, today announced the initiation of its first-in-human Phase 1 clinical trial of Lm-LLO-TT in patients with unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC).

      The clinical trial (NCT07828236) is now recruiting patients at Montefiore Medical Center in New York. The study marks an important milestone for Matter Bio and its subsidiary Loki Therapeutics as it advances its novel immunotherapy platform into clinical development.

      "Rather than teaching the immune system something entirely new, we aim to harness the immune memory patients already have and redirect it toward cancer." — Sam Sharifi, PhD, Chief Scientific Officer, Matter Bio

      Post this

      Pancreatic cancer remains one of the most difficult cancers to treat, particularly in patients whose disease cannot be surgically removed. Despite advances in treatment, patients with advanced disease continue to face limited therapeutic options.

      Lm-LLO-TT takes a different approach to cancer immunotherapy. The investigational therapy uses an attenuated strain of Listeria monocytogenes engineered to express a tetanus toxoid antigen. By leveraging the body's existing immune memory against tetanus, the therapy is designed to activate T cells and redirect immune responses toward tumors.

      "Reaching the clinic is an important milestone for our team and for everyone who has contributed to developing this therapy," said Christopher Bradley, CEO of Matter Bio. "Pancreatic cancer remains incredibly challenging to treat, and we believe this approach offers a promising new avenue worth exploring. We are excited to begin evaluating Lm-LLO-TT in patients."

      The open-label, dose-escalation Phase 1 study will evaluate the safety, tolerability, and appropriate dosing of Lm-LLO-TT administered intraperitoneally in combination with low-dose gemcitabine. The study plans to enroll up to 18 patients with previously treated unresectable or metastatic PDAC and will also assess preliminary anti-tumor activity and immune responses.

      "Our approach is based on a simple idea: rather than teaching the immune system something entirely new, we want to harness the strong immune memory that patients already have against tetanus and redirect it toward cancer," said Sam Sharifi, PhD, Chief Scientific Officer of Matter Bio. "After years of preclinical development, we are excited to bring this approach into the clinic. This trial is an important first step toward understanding its potential for patients with pancreatic cancer."

      Clinical Trial: The trial is registered on ClinicalTrials.gov under identifier NCT07828236. https://clinicaltrials.gov/study/NCT07828236

      About Matter Bio

      Matter Bio is a biotechnology company developing technologies and therapeutics to address fundamental drivers of disease, with a focus on genomic integrity and cancer. By combining advances in molecular biology, genomics, and immunotherapy, Matter Bio aims to develop innovative approaches to treating complex diseases and improving human health.

      For more information, visit www.matter.bio.

      Forward-Looking Statements

      This press release contains forward-looking statements regarding the clinical development of Lm-LLO-TT, including the conduct of the Phase 1 trial, potential therapeutic benefits, and future development plans. These statements involve risks and uncertainties, and actual results may differ materially from current expectations. Lm-LLO-TT is investigational and has not been approved by the FDA or any other regulatory authority.

      Media Contact: [email protected]

      Media Contact

      Media Team, Matter Bio, 1 8087813434, [email protected], http://www.matter.bio

      SOURCE Matter Bio

      Modal title

      Illustration of Matter Bio’s Listeria-based immunotherapy designed to activate immune responses against cancer.
      Illustration of Matter Bio’s Listeria-based immunotherapy designed to activate immune responses against cancer.

      Contact PRWeb

      • 11AM ET Sunday – 8PM ET Friday
      • Contact Us

      About PRWeb

      • About PRWeb
      • Partners
      • Partnership Programs
      • Editorial Guidelines
      • Resources

      Why PRWeb

      • Why PRWeb
      • How It Works
      • Who Uses It
      • Pricing

      Accounts

      • Create a Free Account
      • Log in
      • Contact Us

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact Cision

      Products

      About

      My Services
      • All News Releases
      • Online Member Center
      • ProfNet
      Cision Distribution Helpline
      888-776-0942
      • Legal
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 Cision US Inc.